TCGA-NJ-A55A-01A-11R-A262-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 76
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.270
- BILE_ACID_METABOLISM+0.210
- MYOGENESIS+0.210
- HEDGEHOG_SIGNALING+0.180
- NOTCH_SIGNALING+0.180
- KRAS_SIGNALING_DN+0.150
- ALLOGRAFT_REJECTION+0.130
- WNT_BETA_CATENIN_SIGNALING+0.100
- INTERFERON_GAMMA_RESPONSE+0.050
- IL6_JAK_STAT3_SIGNALING+0.040
Top 10 suppressed
- E2F_TARGETS-0.660
- MYC_TARGETS_V2-0.660
- MYC_TARGETS_V1-0.630
- G2M_CHECKPOINT-0.600
- MTORC1_SIGNALING-0.600
- OXIDATIVE_PHOSPHORYLATION-0.540
- UNFOLDED_PROTEIN_RESPONSE-0.520
- GLYCOLYSIS-0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.450
- CHOLESTEROL_HOMEOSTASIS-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-A4DG-01A-11R-A24H-07 | — | cohortA1 | 0.922 |
| 2 | SRR8526730 | — | cohortA1 | 0.909 |
| 3 | TCGA-75-7025-01A-12R-1949-07 | — | cohortA1 | 0.905 |
| 4 | TCGA-44-6148-01A-11R-1755-07 | — | cohortA1 | 0.903 |
| 5 | C3N-00293 | — | cohortA1 | 0.898 |
| 6 | TCGA-55-A48X-01A-11R-A24H-07 | — | cohortA1 | 0.892 |
| 7 | TCGA-91-8497-01A-11R-2403-07 | — | cohortA1 | 0.891 |
| 8 | TCGA-97-8552-01A-11R-2403-07 | — | cohortA1 | 0.891 |
| 9 | BS_C80S5N37 | EPN | EPN Tumor | 0.890 |
| 10 | SRR2016932 | — | — | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.050 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.040 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |